His primary areas of investigation include Sepsis, Septic shock, Immunology, Internal medicine and Intensive care medicine. His specific area of interest is Sepsis, where Steven M. Opal studies Organ dysfunction. His biological study spans a wide range of topics, including Shock, Retrospective cohort study, Intensive care, SOFA score and Endothelium.
He combines subjects such as Gastroenterology, Placebo and Surgery with his study of Internal medicine. His studies deal with areas such as Severe sepsis, Surviving Sepsis Campaign, MEDLINE, ARDS and Disease as well as Intensive care medicine. In his work, Lactate clearance, Sepsis mortality and Pediatric sepsis is strongly intertwined with Sepsis Six, which is a subfield of Surviving Sepsis Campaign.
The scientist’s investigation covers issues in Sepsis, Immunology, Intensive care medicine, Septic shock and Internal medicine. His primary area of study in Sepsis is in the field of Organ dysfunction. The various areas that Steven M. Opal examines in his Intensive care medicine study include Severe sepsis, Antibiotics, MEDLINE and Pneumonia.
His Septic shock study combines topics from a wide range of disciplines, such as Disseminated intravascular coagulation and Shock. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo, Surgery and Bacteremia. His Microbiology research incorporates themes from Lipopolysaccharide, Bacterial outer membrane, Escherichia coli and Bacteria.
Steven M. Opal mainly focuses on Sepsis, Intensive care medicine, Immunology, Septic shock and Antibiotics. His Sepsis research focuses on Randomized controlled trial and how it relates to Placebo. Steven M. Opal focuses mostly in the field of Intensive care medicine, narrowing it down to matters related to Precision medicine and, in some cases, Clinical research.
His Immunology course of study focuses on Receptor and Pharmacology. His Septic shock research incorporates elements of Randomization, SOFA score and Immune system. As a part of the same scientific study, Steven M. Opal usually deals with the Systemic inflammatory response syndrome, concentrating on Intensive care and frequently concerns with Mortality rate.
His primary areas of study are Sepsis, Intensive care medicine, Immunology, Septic shock and Placebo. Steven M. Opal studies Systemic inflammatory response syndrome, a branch of Sepsis. His studies in Systemic inflammatory response syndrome integrate themes in fields like Surviving Sepsis Campaign and Sepsis Six.
His research in Intensive care medicine is mostly focused on Intensive care. His research integrates issues of Receptor, Antibiotic resistance and Endothelial dysfunction in his study of Immunology. His Septic shock study combines topics in areas such as Shock, Barrier function, SOFA score, Randomization and Innate immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.
Dellinger Rp;Levy Mm;Rhodes A;Annane D.
Critical Care Medicine (2013)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer;Clifford S. Deutschman;Christopher Warren Seymour;Manu Shankar-Hari.
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
R. Phillip Dellinger;Mitchell M. Levy;Andrew Rhodes;Djillali Annane.
Intensive Care Medicine (2013)
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Mitchell M. Levy;Mitchell P. Fink;John C. Marshall;Edward Abraham.
Critical Care Medicine (2003)
Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury
John A. Kellum;Norbert Lameire;Peter Aspelin;Rashad S. Barsoum.
Kidney International (2012)
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Charles J. Fisher;Jan M. Agosti;Steven M. Opal;Stephen F. Lowry.
The New England Journal of Medicine (1996)
Steven M. Opal;Vera A. DePalo.
High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial
Brian L. Warren;Alain Eid;Pierre Singer;Subramanion S. Pillay.
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Charles J. Fisher;Jean-Francois A. Dhainaut;Steven M. Opal;John P. Pribble.
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Edward Abraham;Konrad Reinhart;Steven Opal;Ignace Demeyer.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: